Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Strickler on the Benefit of Combining Tucatinib With Trastuzumab in HER2+ CRC

October 14th 2022

John H. Strickler, MD, discusses the benefit of combining tucatinib with trastuzumab in HER2-positive metastatic colorectal cancer.

CAR T-cell Therapy CYAD-101 No Longer Under Development for Metastatic CRC

October 14th 2022

Celyad Oncology has discontinued development its investigational CAR T-cell therapy CYAD-101 for the treatment of patients with unresectable metastatic colorectal cancer.

Dr. Dasari on the Investigation of Fruquintinib in mCRC

October 6th 2022

Nageshwara Arvind Dasari, MD, discusses the patient population observed in the phase 3 FRESCO-2 trial in metastatic colorectal cancer.

Dr. Strickler on the Importance of Targeted Therapies in HER2+ mCRC

October 5th 2022

John H. Strickler, MD, discusses the importance of investigating targeted therapies in HER2-positive metastatic colorectal cancer.

Tucatinib plus trastuzumab in patients (pts) with HER2-Positive Metastatic Colorectal Cancer (mCRC): Patient Reported Outcomes from MOUNTAINEER

October 5th 2022

Dr Hubbard reviews patient reported outcomes from the MOUNTAINEER trial, which evaluated the combination of tucatinib plus trastuzumab in patients with HER2-positive metastatic colorectal cancer.

SCO-101 Plus FOLFIRI Will Continue to Be Studied Despite Missing Primary End Point in mCRC

October 4th 2022

The addition of SCO-101 to FOLFIRI chemotherapy was safe and tolerable but failed to elicit a greater than 30% reduction in tumor volume in patients with metastatic colorectal cancer, though study of the combination will continue.

Fruquintinib Provides Significant Survival Benefits in Heavily Pretreated mCRC

September 26th 2022

Nageshwara Arvind Dasari, MD, discusses the results of the phase 3 FRESCO-2 trial of fruquintinib in patients with refractory metastatic colorectal cancer, the significance of the data for the treatment paradigm, and the potential next steps for examining the agent in this disease.

Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer (HER2+ mCRC): A Systematic Literature Review and Meta-Analysis of Clinical Outcomes

September 23rd 2022

Dr. Tanios Bekaii-Saab discusses the results of a systematic review/meta-analysis intended to assess the impact of EGFR-targeted therapies on clinical outcomes in patients with HER2-positive metastatic colorectal cancer.

FDA Grants Priority Review to Tucatinib/Trastuzumab Combo for Previously Treated HER2+ mCRC

September 19th 2022

The FDA has granted a priority review to a supplemental new drug application seeking the approval of tucatinib for use in combination with trastuzumab in adult patients with HER2-positive colorectal cancer who have received at least 1 prior treatment regimen for unresectable or metastatic disease.

Dose-Optimized Regorafenib Leads to Improved Survival in mCRC

September 16th 2022

Dose optimization of regorafenib led to improved survival outcomes compared with best supportive care of fruquintinib, standard-dose regorafenib, and trifluridine/tipiracil in patients with relapsed/refractory metastatic colorectal cancer.

TAS-102/Bevacizumab Combo Improves OS Over TAS-102 Alone in Refractory mCRC

September 13th 2022

The addition of bevacizumab to trifluridine/tipiracil resulted in a statistically significant improvement in overall survival over trifluridine/tipiracil alone in patients with refractory metastatic colorectal cancer after 2 chemotherapy regimens.

Adagrasib With or Without Cetuximab Elicits Responses in Advanced KRAS G12C–Mutated CRC

September 12th 2022

Adagrasib monotherapy and in combination with cetuximab generated encouraging responses in patients with advanced colorectal cancer harboring KRAS G12C mutations.

Tucatinib Plus Trastuzumab Elicits Responses in Crossover Cohort in HER2+ mCRC

September 12th 2022

Tucatinib plus trastuzumab improved radiographic response rates in patients with metastatic HER2-positive colorectal cancer initially treated with tucatinib monotherapy who later crossed over to receive doublet therapy.

Neoadjuvant Nivolumab/Ipilimumab Elicits Promising Pathologic Responses in dMMR Colon Cancer

September 11th 2022

Four weeks of treatment with nivolumab plus ipilimumab elicited major pathologic responses in 95% of patients with mismatch repair–deficient colon cancer.

Neoadjuvant Therapy Holds Promise for Patients With Locally Advanced Rectal Cancer

September 4th 2022

Research published in 2022 has advanced our understanding of the effect of neoadjuvant therapy on organ preservation for patients with locally advanced rectal cancer.

Neoadjuvant Chemotherapy Elicits Necessary Responses for Organ-Sparing Surgery in Early-Stage Rectal Cancer

September 1st 2022

Chemotherapy prior to transanal excision surgery demonstrated favorable responses that led to increased organ preservation rates among patients with early rectal cancer, according to findings from the phase 2 NEO trial.

Dr. Shaukat on the Benefit of Diverse Enrollment in Clinical Trials in CRC

August 31st 2022

Aasma Shaukat, MD, MPH, discusses the benefit of diverse enrollment in clinical trials in colorectal cancer.

Encorafenib/Cetuximab ± Binimetinib Improves Survival Regardless of Age in BRAF V600E–Mutant mCRC

August 30th 2022

Treatment with either encorafenib plus cetuximab with or without binimetinib or standard chemotherapy each demonstrated comparable progression-free survival and overall survival in pretreated patients with BRAF V600E–mutated metastatic colorectal cancer.

Dr. Strickler on the Exploration of Frontline Tucatinib/Trastuzumab in HER2+ CRC

August 29th 2022

John H. Strickler, MD, discusses the investigation of frontline tucatinib plus trastuzumab in HER2-positive colorectal cancer.

Larotrectinib Maintains Long-Term Efficacy in Advanced GI Cancers Harboring NTRK Fusions

August 25th 2022

Larotrectinib produced durable responses in patients with NTRK fusion–positive locally advanced or metastatic gastrointestinal cancer, particularly in those with colorectal cancer.